The growth in the forecast period can rising incidence of rare genetic disorders, expansion of healthcare infrastructure in emerging markets, advancements in biopharmaceutical technologies, increased government support for rare disease treatments, ongoing development of complementary and advanced therapies. Major trends in increasing adoption of enzyme replacement therapies (ERT), focus on personalized and precision medicine, expansion of patient access programs for rare diseases, growing investments in biopharmaceutical r&d, technological advancements in drug delivery systems.
The growing incidence of rare genetic disorders is expected to drive the expansion of the elaprase market in the future. Rare genetic disorders are conditions caused by genetic abnormalities that occur infrequently in the population. The increasing diagnosis and awareness of these disorders, coupled with regulatory advancements, are fueling the demand for Elaprase. Elaprase plays a crucial role in treating rare genetic disorders such as Hunter syndrome by replenishing the deficient enzyme iduronate-2-sulfatase, helping to reduce harmful sugar accumulation, improve organ function, and enhance the quality of life for patients. For example, in February 2023, the Rady Children's Institute for Genomic Medicine reported that 41% of infant deaths were attributed to single-locus (Mendelian) genetic diseases in a study conducted at Rady Children’s Hospital. Therefore, the rising incidence of rare genetic disorders is contributing to the growth of the elaprase market.
The growing emphasis on personalized medicine is expected to further boost the elaprase market. Personalized medicine tailors treatments and therapies to an individual's genetic makeup, environment, and lifestyle. The rising demand for personalized medicine is driven by advancements in genomic medicine, an increase in chronic diseases, improved diagnostic technologies, and a shift towards patient-centered healthcare. Elaprase (idursulfase) functions as a personalized treatment by replacing the deficient or defective iduronate-2-sulfatase enzyme in patients with Hunter syndrome, tailoring the therapy to address the specific enzyme deficiency and helping to alleviate symptoms based on individual metabolic needs. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. As a result, the growing focus on personalized medicine is driving the growth of the elaprase market.
A key trend in the elaprase market is the emphasis on conducting clinical trials to explore new therapeutic applications, improve treatment efficacy, and expand its use to address unmet medical needs in patients with Hunter syndrome. These trials aim to optimize dosing regimens, improve patient outcomes, and potentially reduce side effects associated with enzyme replacement therapy. For example, in August 2024, Takeda Pharmaceuticals, a US-based pharmaceutical company, announced a study focusing on the safety profile of elaprase in Indian children and adults with Hunter syndrome. This study aims to gather additional data on the drug's efficacy and safety across diverse populations.
The key company operating in the elaprase market is Takeda Pharmaceutical Company.
North America was the largest region in the elaprase market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elaprase report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the elaprase market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elaprase (idursulfase) is a recombinant enzyme replacement therapy used to treat Hunter syndrome (Mucopolysaccharidosis II, or MPS II), a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. Elaprase works by replacing the missing enzyme, which helps break down glycosaminoglycans (GAGs) and reduce their accumulation, thus alleviating symptoms and slowing the progression of the disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for elaprase include Hunter syndrome (MPS II) and other related conditions. Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare genetic disorder caused by a lack or deficiency of the enzyme iduronate-2-sulfatase (I2S). The patient population for elaprase includes adults, pediatric patients, and geriatric patients, with distribution through various channels such as hospital pharmacies, specialty treatment pharmacies, and retail pharmacies. The end users of elaprase include hospitals, clinics, ambulatory care settings, and home care services.
The elaprase market consists of sales of vial formulation, single-dose vial, and multi-dose packaging. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Elaprase Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on elaprase market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for elaprase ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The elaprase market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Hunter Syndrome (MPS II); Other Indications2) By Patient Type: Adults; Pediatrics; Geriatrics
3) By Distribution Channel: Hospital Pharmacies; Specialty Treatment Pharmacies; Retail Pharmacies
4) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: Takeda Pharmaceutical Company
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Takeda Pharmaceutical Company